Rapid Dose Thera Stock Price, News & Analysis

Rapid Dose Therapeutics (RDTCF) has announced plans for an equity private placement financing to raise up to $3 million in gross proceeds. The financing will offer up to 13,636,364 units at $0.22 per unit, with each unit comprising one common share and one warrant. The warrants will be exercisable at $0.34 per share for a two-year term.

Meadowbank Asset Management will serve as the agent, receiving a 6% cash commission and 6% in agent warrants from investors they introduce. The proceeds will be used for research and development, capital expansion, and working capital. The securities will have a four-month hold period from closing.

Rapid Dose Therapeutics (RDTCF) and Aavishkar Oral Strips have filed two crucial patent applications for innovative nicotine delivery technology. The patents cover both dissolvable and non-dissolvable oral nicotine strips using RDT's QuickStrip™ platform. The dissolvable variant enables nicotine delivery in under 2 minutes, while the non-dissolvable version offers extended release in a slim format.

The international PCT applications filed with WIPO extend protection to 158 jurisdictions worldwide. This development follows a pre-commercialization agreement with a leading global tobacco company announced in January 2025. The technology aims to provide a safer alternative for the 1.3 billion global tobacco users, targeting the 60% of smokers wanting to quit.

Rapid Dose Therapeutics (RDTCF) has announced a debt settlement agreement with certain creditors. The company plans to issue up to 2.5 million common shares in exchange for canceling approximately $500,000 in outstanding accounts payable. The Settlement Shares will be issued at $0.20 per share.

The transaction aims to improve RDT's financial position by reducing existing liabilities. Settlement Shares issued to Canadian residents will have a four-month hold period. The agreement requires Canadian Securities Exchange approval and will not create a new control person of the company.

Rapid Dose Therapeutics (RDTCF) has provided an update on its collaboration with the University of Regina's Faculty of Kinesiology & Health Studies for an NFL-funded medical cannabis research project. The study focuses on examining cannabinoids' effects on sport concussion and pain management.

The project has entered the clinical trial phase, investigating the bioavailability of CBD through RDT's QuickStrip™ sublingual delivery system compared to standard oral formulation. The randomized, two-arm clinical study, approved by Health Canada, involves researchers from the Universities of Regina, Saskatchewan, and British Columbia.

The study specifically examines the pharmacokinetic parameters of non-psychoactive cannabidiol (CBD) and its metabolites in healthy young adults. The QuickStrip™ technology consists of rectangular oral thin films infused with cannabis extract that dissolve under the tongue, releasing the compound directly into the mucus membranes.

Rapid Dose Therapeutics (CSE: DOSE) has announced its participation in major dental tradeshows across Canada to showcase XyliStrip, an oral dissolving thin film strip powered by QuickStrip technology. The product is designed to address dry mouth (Xerostomia), which affects over 20% of the population and is one of North America's fastest-growing oral health problems.

XyliStrip utilizes RDT's proprietary sublingual thin film strip technology that can be infused with various active ingredients, including Nutraceuticals, Pharmaceuticals, Cannabis, and Nicotine, for rapid bloodstream delivery. The company will present at seven major dental events from April to October 2025, including the Women In Dentistry Symposium, Ontario Society of Periodontists Spring Meeting, and the American Association of Periodontology & Canadian Association of Periodontists Joint Meeting.

Rapid Dose Therapeutics (CSE: DOSE) has announced plans to issue common shares to satisfy the quarterly interest payment due March 31, 2025, on its secured convertible notes. The company will issue 463,716 common shares at $0.20 per share, totaling $92,745.22 in accrued interest.

The notes, issued in 2023 through a private placement financing of $3,134,445, carry a 12% annual interest rate and mature on November 30, 2025. The financing included units priced at $1.00, each comprising notes and five common share purchase warrants, resulting in 15,672,225 warrants issued.

Additionally, RDT has received an extension from the CSE until April 24, 2025, to complete its previously announced shares-for-debt transaction. This transaction involves issuing up to 1,600,000 common shares at $0.25 per share to settle approximately $400,000 in outstanding accounts payable with creditors.

Rapid Dose Therapeutics Corp (CSE: DOSE) has announced plans for an equity private placement financing to raise up to $5,000,000 in gross proceeds. The financing will consist of up to 20,833,333 common shares priced at $0.24 per share.

The company has engaged Meadowbank Asset Management Inc. as the agent, who will receive a 1% cash commission on proceeds from investors they introduce, plus agent warrants equal to 6% of shares issued to their referred investors. Each agent warrant will be exercisable at $0.33 per share for two years.

The proceeds will be used for debt retirement, research and development, capital expansion, and working capital. The financing may close in multiple tranches, with securities subject to a four-month hold period.

Rapid Dose Therapeutics (CSE: DOSE) has expanded its collaboration with an unnamed international company in oral nicotine products through an exclusive pre-commercialization agreement extending to June 19, 2025. The agreement involves RDT providing project management and product development services for a monthly fee of USD$120,000.

The collaboration, which began in December 2022, focuses on finalizing innovative, market-ready products for launch in 2025. Key development areas include formulation optimization, packaging enhancement, consumer studies, product benchmarking, and regulatory documentation preparation. The partnership leverages RDT's proprietary QuickStrip™ Oral Thin Film (OTF) technology to develop next-generation smoke-free alternatives.

Rapid Dose Therapeutics (CSE: DOSE) has received an extension from the Canadian Securities Exchange for its previously announced debt settlement transaction. The extension allows the company to close the Shares for Debt Transaction by March 10, 2025. The transaction involves issuing up to 1,600,000 common shares at $0.25 per share to creditors in exchange for canceling approximately $400,000 in outstanding accounts payable.

Additionally, the company announced it will not proceed with the previously disclosed private placement of units (shares and warrants) worth up to $6,000,000 at this time.